Fennec Pharmaceuticals Inc., (NASDAQ: FENC; TSX: FRX) is a commercial stage specialty pharmaceutical company focused on the development of PEDMARK® (sodium thiosulfate injection). PEDMARK is the first and only FDA-approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin in pediatric patients with localized, non-metastatic solid tumors. In October 2022, Fennec commercially launched PEDMARK in the United States. 

PEDMARK received Orphan Drug designation by the FDA in 2004. The Marketing Authorization Application (MAA) for sodium thiosulfate (tradename PEDMARQSI) is currently under evaluation by the European Medicines Agency (EMA).